...
首页> 外文期刊>BMC Gastroenterology >Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt
【24h】

Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt

机译:Budd-Chiari综合征:经颈静脉肝内门-系统分流术通过肝减压可取得长期成功

获取原文
           

摘要

Background Budd-Chiari syndrome (BCS) generally implies thrombosis of the hepatic veins and/or the intrahepatic or suprahepatic inferior vena cava. Treatment depends on the underlying cause, the anatomic location, the extent of the thrombotic process and the functional capacity of the liver. It can be divided into medical treatment including anticoagulation and thrombolysis, radiological procedures such as angioplasty and transjugular intrahepatic porto-systemic shunt (TIPS) and surgical interventions including orthotopic liver transplantation (OLT). Controlled trials or reports on larger cohorts are limited due to rare disease frequency. The aim of this study was to report our single centre long term results of patients with BCS receiving one of three treatment options i.e. medication only, TIPS or OLT on an individually based decision of our local expert group. Methods 20 patients with acute, subacute or chronic BCS were treated between 1988 and 2008. Clinical records were analysed with respect to underlying disease, therapeutic interventions, complications and overall outcome. Results 16 women and 4 men with a mean age of 34 ± 12 years (range: 14-60 years) at time of diagnosis were included. Myeloproliferative disorders or a plasmatic coagulopathy were identified as underlying disease in 13 patients, in the other patients the cause of BCS remained unclear. 12 patients presented with an acute BCS, 8 with a subacute or chronic disease. 13 patients underwent TIPS, 4 patients OLT as initial therapy, 2 patients required only symptomatic therapy, and one patient died from liver failure before any specific treatment could be initiated. Eleven of 13 TIPS patients required 2.5 ± 2.4 revisions (range: 0-8). One patient died from his underlying hematologic disease. The residual 12 patients still have stable liver function not requiring OLT. All 4 patients who underwent OLT as initial treatment, required re-OLT due to thrombembolic complications of the graft. Survival in the TIPS group was 92.3% and in the OLT group 75% during a median follow-up of 4 and 11.5 years, respectively. Conclusion Our results confirm the role of TIPS in the management of patients with acute, subacute and chronic BCS. The limited number of patients with OLT does not allow to draw a meaningful conclusion. However, the underlying disease may generate major complications, a reason why OLT should be limited to patients who cannot be managed by TIPS.
机译:背景Budd-Chiari综合征(BCS)通常意味着肝静脉和/或肝内或肝上下腔静脉血栓形成。治疗取决于根本原因,解剖位置,血栓形成过程的程度和肝脏的功能能力。它可以分为包括抗凝和溶栓在内的医学治疗,诸如血管成形术和经颈静脉肝内门-全身分流术(TIPS)等放射学程序以及包括原位肝移植(OLT)在内的外科手术。由于罕见疾病的发病率,有关较大人群的对照试验或报告受到限制。这项研究的目的是根据我们当地专家组的个人决定,报告接受三种治疗方法之一的BCS患者的单中心长期结果,即仅使用药物,TIPS或OLT。方法1988年至2008年间,对20例急性,亚急性或慢性BCS患者进行了治疗。分析了相关疾病,治疗措施,并发症和总体预后的临床记录。结果包括16位女性和4位男性,诊断时平均年龄为34±12岁(范围:14-60岁)。骨髓增生性疾病或血浆凝血病被确定为13例患者的基础疾病,其他患者中BCS的病因尚不清楚。 12例患有急性BCS,8例患有亚急性或慢性疾病。 13例患者接受了TIPS,4例接受OLT作为初始治疗,2例仅需要对症治疗,并且1例患者在开始任何特殊治疗之前死于肝衰竭。 13位TIPS患者中有11位需要2.5±2.4修订版(范围:0-8)。一名患者死于其潜在的血液学疾病。剩余的12名患者仍具有稳定的肝功能,不需要OLT。接受OLT作为初始治疗的所有4例患者由于移植物的血栓栓塞并发症而需要再次OLT。在中位随访4年和11.5年中,TIPS组的生存率分别为92.3%和OLT组的75%。结论我们的结果证实了TIPS在急性,亚急性和慢性BCS患者管理中的作用。数量有限的OLT患者无法得出有意义的结论。但是,潜在疾病可能会产生重大并发症,这就是将OLT限于无法通过TIPS进行治疗的患者的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号